These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 24326693)

  • 1. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A).
    Hauser RA; Hewitt LA; Isaacson S
    J Parkinsons Dis; 2014; 4(1):57-65. PubMed ID: 24326693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B).
    Hauser RA; Isaacson S; Lisk JP; Hewitt LA; Rowse G
    Mov Disord; 2015 Apr; 30(5):646-54. PubMed ID: 25487613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension.
    Hauser RA; Heritier S; Rowse GJ; Hewitt LA; Isaacson SH
    Clin Neuropharmacol; 2016; 39(5):220-6. PubMed ID: 27332626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension.
    Biaggioni I; Arthur Hewitt L; Rowse GJ; Kaufmann H
    BMC Neurol; 2017 May; 17(1):90. PubMed ID: 28494751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial.
    Kaufmann H; Freeman R; Biaggioni I; Low P; Pedder S; Hewitt LA; Mauney J; Feirtag M; Mathias CJ;
    Neurology; 2014 Jul; 83(4):328-35. PubMed ID: 24944260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of droxidopa in patients with neurogenic orthostatic hypotension: post-hoc economic analysis of Phase 3 clinical trial data.
    François C; Hauser RA; Aballéa S; Dorey J; Kharitonova E; Hewitt LA
    J Med Econ; 2016; 19(5):515-25. PubMed ID: 26710315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa.
    Biaggioni I; Freeman R; Mathias CJ; Low P; Hewitt LA; Kaufmann H;
    Hypertension; 2015 Jan; 65(1):101-7. PubMed ID: 25350981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurogenic orthostatic hypotension in Parkinson's disease: evaluation, management, and emerging role of droxidopa.
    Isaacson SH; Skettini J
    Vasc Health Risk Manag; 2014; 10():169-76. PubMed ID: 24729712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis of the safety and efficacy of droxidopa for neurogenic orthostatic hypotension.
    Elgebaly A; Abdelazeim B; Mattar O; Gadelkarim M; Salah R; Negida A
    Clin Auton Res; 2016 Jun; 26(3):171-80. PubMed ID: 26951135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Durability of Effect with Long-Term, Open-Label Droxidopa Treatment in Patients with Symptomatic Neurogenic Orthostatic Hypotension (NOH303).
    Isaacson S; Shill HA; Vernino S; Ziemann A; Rowse GJ
    J Parkinsons Dis; 2016 Oct; 6(4):751-759. PubMed ID: 27636856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension.
    François C; Rowse GJ; Hewitt LA; Vo P; Hauser RA
    BMC Neurol; 2016 Aug; 16(1):143. PubMed ID: 27538531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Norepinephrine precursor therapy in neurogenic orthostatic hypotension.
    Kaufmann H; Saadia D; Voustianiouk A; Goldstein DS; Holmes C; Yahr MD; Nardin R; Freeman R
    Circulation; 2003 Aug; 108(6):724-8. PubMed ID: 12885750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated Analysis of Droxidopa for the Treatment of Neurogenic Orthostatic Hypotension in Patients with Parkinson Disease.
    Hauser RA; Biaggioni I; Hewitt LA; Vernino S
    Mov Disord Clin Pract; 2018; 5(6):627-634. PubMed ID: 30637284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases.
    Pérez-Lloret S; Quarracino C; Otero-Losada M; Rascol O
    Expert Opin Pharmacother; 2019 Apr; 20(6):635-645. PubMed ID: 30730771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension.
    Gupta F; Karabin B; Mehdirad A
    Clin Auton Res; 2017 Jul; 27(Suppl 1):15-16. PubMed ID: 28699047
    [No Abstract]   [Full Text] [Related]  

  • 16. Initiating droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease.
    Claassen D; Lew M
    Clin Auton Res; 2017 Jul; 27(Suppl 1):13-14. PubMed ID: 28631224
    [No Abstract]   [Full Text] [Related]  

  • 17. Adjusting droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease.
    Goodman BP; Claassen D; Mehdirad A
    Clin Auton Res; 2017 Jul; 27(Suppl 1):17-19. PubMed ID: 28631223
    [No Abstract]   [Full Text] [Related]  

  • 18. Supine plasma NE predicts the pressor response to droxidopa in neurogenic orthostatic hypotension.
    Palma JA; Norcliffe-Kaufmann L; Martinez J; Kaufmann H
    Neurology; 2018 Oct; 91(16):e1539-e1544. PubMed ID: 30232253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adding droxidopa to fludrocortisone or midodrine in a patient with neurogenic orthostatic hypotension and Parkinson disease.
    Kremens D; Lew M; Claassen D; Goodman BP
    Clin Auton Res; 2017 Jul; 27(Suppl 1):29-31. PubMed ID: 28674867
    [No Abstract]   [Full Text] [Related]  

  • 20. Droxidopa: a review of its use in symptomatic neurogenic orthostatic hypotension.
    Keating GM
    Drugs; 2015 Feb; 75(2):197-206. PubMed ID: 25559422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.